The European Union has announced a new €16.5M funding package to combat a deadly Ebola outbreak in Central Africa, bringing total EU commitment to €31.5M. This initiative directly affects Portuguese-speaking nationals working in humanitarian, diplomatic, and development sectors across the Democratic Republic of Congo (DRC) and neighboring Uganda. The epidemic, now classified as a Public Health Emergency of International Concern (PHEIC), has killed 101 people in less than a month and threatens regional stability in a conflict zone where armed militias control key access routes.
What Portugal Residents Need to Know
For residents living in Portugal, the immediate risk from this Ebola outbreak remains low. The WHO has assessed global risk as minimal, and Portugal's health surveillance systems are equipped to detect and isolate imported cases.
However, if you have traveled to affected regions (Ituri, North Kivu, or South Kivu in the DRC, or Uganda) within the past 21 days, monitor yourself for symptoms. Fever, severe fatigue, muscle pain, or sore throat appearing during this period warrant immediate medical attention—inform your healthcare provider of your travel history.
For Portuguese nationals and expats working in the DRC or Uganda, particularly in humanitarian aid, mining, energy, and diplomatic sectors, practical precautions are essential:
• Avoid all non-essential travel to Ituri, North Kivu, and South Kivu provinces.
• Monitor border closures and travel restrictions between DRC and Uganda, which may change without notice.
• Ensure employer-provided health insurance covers emergency medical evacuation, as treatment capacity in-country is limited.
• Contact the Portuguese Ministry of Foreign Affairs for updated travel advisories and consular support. The ministry has not issued a specific travel alert for Portugal-based residents, as risk assessments focus on those actively working in affected regions.
Why This Matters
• No approved vaccine or treatment exists for the Bundibugyo strain causing this outbreak, unlike the more common Zaire strain.
• 550 confirmed cases reported in the DRC as of June 7, with 101 deaths and only 19 recoveries.
• Armed conflict in Ituri province is blocking health workers from reaching infected communities.
• Cross-border spread to Uganda has prompted temporary border closures and heightened surveillance protocols.
The Outbreak: Bundibugyo Complicates Response
This marks the 17th Ebola epidemic in the DRC since the virus was first identified near the Ebola River in 1976. What makes this outbreak uniquely challenging is the pathogen responsible: the Bundibugyo ebolavirus, a rare strain that lacks the medical countermeasures developed for its better-known cousin, the Zaire strain.
The Zaire ebolavirus — responsible for the catastrophic 2013–2016 West Africa epidemic that killed more than 11,000 people — has licensed vaccines and monoclonal antibody treatments. The Bundibugyo strain does not. Historically, Bundibugyo has shown fatality rates between 25% and 50%, though the current outbreak's case fatality rate sits at 17.4%, lower than earlier episodes but still deadly in a region where healthcare infrastructure is fragmented.
Transmission occurs through direct contact with blood, vomit, feces, urine, saliva, sweat, semen, or other bodily fluids of infected individuals or animals. Unlike respiratory viruses, Ebola does not spread through the air or water, but close-contact scenarios — common in caregiving, burial rituals, and overcrowded displacement camps — create ideal conditions for outbreaks to accelerate.
Symptoms begin with fever, severe fatigue, muscle pain, headache, and sore throat, easily mistaken for malaria or typhoid in endemic areas. As the disease progresses, patients suffer vomiting, severe diarrhea (often bloody), abdominal pain, skin rashes, and liver and kidney dysfunction. Internal and external hemorrhaging can occur, though gastrointestinal symptoms are more pronounced with Bundibugyo than with Zaire.
Ituri Province: The Epicenter
The outbreak is concentrated in Ituri province, a mineral-rich area in eastern DRC that has been affected by conflict for decades. Of the 550 confirmed cases, 518 are in Ituri, spread across 17 health zones. Kivu do Norte has recorded 29 cases in seven zones, and Kivu do Sul three cases in one zone.
Access to the epicenter — particularly the capital Bunia and surrounding districts like Djugu, Irumu, and Mambasa — is severely restricted due to ongoing instability. Armed groups operating in the region have attacked health workers, destroyed clinics, and forced mass displacement.
More than 7 million people are internally displaced across eastern DRC, many living in unsanitary camps where disease spreads rapidly. Health teams have faced resistance from skeptical or hostile communities, with burial crews and treatment centers targeted. In some areas, residents refuse post-mortem sample collection, citing distrust of authorities or cultural objections, further hampering epidemiological tracking.
European Union Crisis Management Commissioner Hadja Lahbib, during a visit to Bunia, called for humanitarian access. "We cannot build trust in communities or isolate the sick while the security situation remains unstable," she said, echoing a statement from the World Health Organization (WHO).
Uganda: Early Detection, Limited Spread
Uganda has confirmed 19 Ebola cases as of June 8, with two deaths — both individuals who had traveled from the DRC. Of the 19 cases, 14 are linked to cross-border travel and five represent local transmission within Uganda.
The Ugandan government closed its border with the DRC on May 27, a decision aimed at limiting imported cases. WHO Director-General Tedros Adhanom Ghebreyesus visited Uganda this week to assess the response, praising the country's border screening protocols, surveillance systems, and case management. "The government has implemented a rapid and effective response," he said on social media platform X. "The controls at the borders have allowed detection of cases coming from neighboring DRC, and the surveillance, contact tracing, and case management systems are functioning continuously."
The WHO classifies the risk in Uganda as "high," but the country remains far less affected than the DRC. For the broader African continent, the WHO downgraded the risk from "high" to "low" on June 8, while maintaining a "very high" risk classification for the DRC itself.
International Funding and Scientific Pipeline
The European Union's €16.5M package announced this week breaks down as follows:
• €6.5M to the Africa Pathogen Genomics Initiative to strengthen viral sequencing and variant tracking.
• €5M in testing equipment, including rapid diagnostic devices and laboratory kits for the Africa CDC.
• €5M to the WHO to bolster surveillance and access to health materials.
This follows an earlier €15M commitment the EU made in May for emergency humanitarian response. In total, Brussels has now allocated €31.5M to the outbreak.
Separately, the WHO and the African Union's health agency, the Africa CDC, launched a $518M (€446M) six-month response plan on June 6, focusing on laboratory capacity, infection prevention, and cross-border coordination.
Africa CDC Director Jean Kaseya praised the EU partnership, adding, "We want to assure you that we will use this money to generate impact and ensure that humanitarian corridors are considered in our response."
The Vaccine and Treatment Gap
No vaccine for Bundibugyo is currently licensed, but three candidate platforms are advancing toward clinical trials:
• rVSV (recombinant vesicular stomatitis virus), the same platform used in the licensed Zaire vaccine, is the most advanced. The International AIDS Vaccine Initiative (IAVI) is developing a single-dose rVSV-Bundibugyo vaccine, which the WHO has identified as the most promising candidate. Clinical trials could begin within 7 to 9 months.
• ChAdOx viral vector, the technology behind the Oxford/AstraZeneca COVID-19 vaccine, offers rapid manufacturing scalability. A ChAdOx1 Bundibugyo candidate developed by the University of Oxford and Serum Institute of India could be ready for efficacy trials within 2 to 3 months, pending additional animal data.
• mRNA platforms, validated during the COVID-19 pandemic, are being explored by Moderna with funding for preclinical and human trials.
The Coalition for Epidemic Preparedness Innovations (CEPI) has committed over $60M to accelerate this vaccine portfolio.
For treatment, three candidate therapies are being prioritized:
• Monoclonal antibodies MBP134 and Maftivimab, which have shown protection in primate studies.
• Remdesivir, an antiviral used against other filoviruses, with prior experience in clinical trials for Zaire Ebola.
• Obeldesivir, an oral antiviral candidate for post-exposure prophylaxis in contacts of confirmed cases.
Clinical trials using the PARTNERS adaptive platform, co-developed by ISARIC and the WHO, are being adapted to evaluate these treatments.
Looking Ahead
The 17.4% case fatality rate in the current outbreak is lower than historical averages for Bundibugyo, but the absolute death toll continues to climb. With only 19 recoveries among 550 cases, the epidemic remains difficult to contain. The absence of a vaccine means that traditional public health interventions — case isolation, contact tracing, safe burial practices, and community engagement — remain the primary tools available.
For residents of Portugal, the story demonstrates how international health crises can affect travel and work abroad, even when direct risk is low. As long as the security situation in eastern DRC hampers health response efforts, the outbreak will remain challenging to suppress. International support, including the EU's €31.5M commitment, aims to strengthen the regional response and prevent further escalation.
